Clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164.
Company Announces New Headquarters, a State-of-the-Art Manufacturing Facility to Expand Commercialization of the Radical Neurovascular Catheter Portfolio to Include a Wide Range of Sizes and ...